NucleoCounter® NC-3000™ publications

Below can find publications where the NucleoCounter NC-3000 is applied in scientific work.

NC-3000 Cell Cycle Assays

Hervouet, E., Vallette, F. M., and Cartron, P.-F. (2010) Dnmt1/Transcription Factor Interactions, Genes & Cancer 1, 434-443.

Download here

NC-3000 Cell Cycle Assays

Myklebust, M. P., Bruland, O., Fluge, O., Skarstein, A., Balteskard, L., and Dahl, O. (2011) MicroRNA-15b is induced with E2F-controlled genes in HPV-related cancer, Br J Cancer.

Download here

NC-3000 Viability and Cell Count + Mitochondrial Potential Assays

Palmfeldt, J., Vang, S., Stenbroen, V., Pavlou, E., Baycheva, M., Buchal, G., Monavari, A. A., Augoustides-Savvopoulou, P., Mandel, H., and Gregersen, N. (2011) Proteomics Reveals that Redox Regulation Is Disrupted in Patients with Ethylmalonic Encephalopathy, Journal of Proteome Research 10, 2389-2396.

Download here

NC-3000 Mitochondrial Potential Assay

Park, S. J., Park, Y. J., Shin, J. H., Kim, E. S., Hwang, J. J., Jin, D.-H., Kim, J. C., and Cho, D.-H. (2011) A receptor tyrosine kinase inhibitor, Tyrphostin A9 induces cancer cell death through Drp1 dependent mitochondria fragmentation, Biochemical and Biophysical Research Communications 408, 465-470.

Download here

NC-3000 Mitochondrial Potential Assay

Park, S.-J., Shin, J.-H., Kang, H., Hwang, J.-J., and Cho, D.-H. (2011) Niclosamide induces mitochondria fragmentation and promotes both apoptotic and autophagic cell death, BMB reports 44, 517-522.

NC-3000 Viability and Cell Count Assay

Zhao, Y.-z., Zhu, J., Zhu, S.-h., Huang, Y.-y., Li, Z.-y., and Zhou, K.-c. (2011) Synthesis and characterization of arginine-modified and europium-doped hydroxyapatite nanoparticle and its cell viability, Transactions of Nonferrous Metals Society of China 21, 1773-1778.

 

ChemoMetec Publications:

A decrease in cellular thiols caused by drug-induced apoptosis is easily quantified using the novel Vitality assay

Mette E. Skindersoe, ChemoMetec A/S

A simple and rapid method for DNA content measurement

Soren Kjaerulff, ChemoMetec A/S